Polypill and Combination Therapy: Blood Pressure and Cardiovascular Risk Reduction

• Published in: Current cardiology reports 2023-12, Vol.25 (12), p.1851-1858
• Main Authors: Park, Jinwook, Yang, Chien-Wen, Huan, Yonghong, Aggarwal, Sandeep
• Format: Article
• Language: English
• Subjects: Antihypertensive Agents - adverse effects; Antihypertensive Agents - therapeutic use; Blood Pressure; Cardiology; Cardiovascular Diseases - chemically induced; Cardiovascular Diseases - prevention & control; Drug Combinations; Heart Disease Risk Factors; Humans; Hypertension (DS Geller and DL Cohen; Medicine; Medicine & Public Health; Risk Factors; Section Editors; Tablets - pharmacology; Topical Collection on Hypertension
• ISSN: 1523-3782; 1534-3170
• DOI: 10.1007/s11886-023-02000-7

Purpose of Review The number of medications prescribed to patients has been progressively increasing, primarily driven by cardioprotective medications. The advent of pharmaceutical 3D printing technology holds the promise of reducing the burden of multiple pills by combining various medications with different release mechanisms into a single tablet. This development encourages a comprehensive review of the evidence supporting the use of combination pills. Recent Findings Recent randomized studies have shown higher BP control rates in quadpill groups than in monotherapy groups and improved 6-month BP control rates with a low-dose triple fixed-dose combination (FDC) medication compared to usual care. Recent randomized controlled trials also support FDC use for primary and secondary prevention of cardiovascular disease. Three-dimensional printing technologies such as powder-based (PB) 3D printing, fused deposition modeling (FDM) 3D printing, and semisolid extrusion (EXT) 3D printing are examples of promising technologies that could be utilized to combine multiple medications with different release mechanisms into a single tablet. Summary FDC therapy can provide patients with combination regimens with a reduced pill burden, which promotes improved adherence and efficacy. Recent randomized trials have shown that FDC can be used for primary and secondary prevention of cardiovascular disease with no significant difference in adverse events. Multidisciplinary approaches should be implemented to enhance long-term adherence, and further research on establishing affordable and effective initial dual antihypertensive therapy options is necessary. Pharmaceutical 3D printing technology may play an important role in enhancing the flexibility, affordability, and feasibility of clinical FDC utilization.